Morgan Stanley forecasts EUR/USD to reach 1.23 by spring before falling

Investing.comMonday, November 24, 2025 at 9:24:01 AM
Morgan Stanley forecasts EUR/USD to reach 1.23 by spring before falling
  • Morgan Stanley has projected that the EUR/USD exchange rate will reach 1.23 by spring 2026 before experiencing a decline. This forecast reflects the bank's analysis of current market conditions and economic indicators affecting the euro and dollar dynamics.
  • This development is significant for investors and traders as it provides insights into potential currency movements, influencing trading strategies and investment decisions in the foreign exchange market. A rise to 1.23 could attract more trading activity around the euro.
  • The forecast comes amid broader discussions about currency stability, with UBS recently lowering its own EUR/USD forecast to 1.20 due to political risks in Europe. Additionally, the Bank of Japan's potential interest rate hikes and the fluctuating dollar against the yen highlight the interconnectedness of global currency markets and the impact of geopolitical factors on exchange rates.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended apps based on your readingExplore all apps
Continue Readings
Revolution Medicines stock hits all-time high at 72.76 USD
PositiveFinancial Markets
Revolution Medicines' stock has reached an all-time high of 72.76 USD, reflecting a significant milestone for the company and indicating strong investor confidence in its performance and future prospects.
Morocco stocks higher at close of trade; Moroccan All Shares up 0.73%
PositiveFinancial Markets
Morocco's stock market closed higher, with the Moroccan All Shares index rising by 0.73%. This positive movement reflects a favorable trading environment and investor sentiment in the region.
Relay Therapeutics stock hits 52-week high at $7.65
PositiveFinancial Markets
Relay Therapeutics' stock has reached a 52-week high of $7.65, reflecting a significant increase in investor confidence and market interest in the company's performance. This milestone highlights the positive sentiment surrounding Relay Therapeutics as it continues to develop innovative therapies.
Amneal Pharmaceuticals stock hits 52-week high at $12.12
PositiveFinancial Markets
Amneal Pharmaceuticals' stock has reached a 52-week high of $12.12, reflecting a significant increase in investor confidence and market performance. This milestone indicates a positive trend for the company as it continues to navigate the competitive pharmaceutical landscape.
European Smaller Companies Trust shareholders approve all resolutions
NeutralFinancial Markets
Shareholders of the European Smaller Companies Trust have approved all resolutions presented during the recent meeting, reflecting a consensus on the company's strategic direction and governance. This decision underscores the shareholders' support for the management's proposals and operational plans.
Disc Medicine stock hits 52-week high at 96.09 USD
PositiveFinancial Markets
Disc Medicine's stock has reached a 52-week high of 96.09 USD, reflecting a significant increase in investor confidence and positive market sentiment. This milestone indicates strong performance and potential growth for the company in the current market landscape.
Wizz Air announces leadership changes effective February 2026
NeutralFinancial Markets
Wizz Air has announced leadership changes that will take effect in February 2026, signaling a shift in the company's management structure. This decision was reported by Investing.com on November 24, 2025.
European Commission approves Omnicom's acquisition of IPG
PositiveFinancial Markets
The European Commission has approved Omnicom's acquisition of IPG, marking a significant step in the consolidation of the advertising and marketing sectors. This approval is expected to enhance Omnicom's market position and expand its service offerings.